{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:56:11Z","timestamp":1788436571745,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["890290"],"award-info":[{"award-number":["890290"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Taighde \u00c9ireann \u2013 Research Ireland","doi-asserted-by":"publisher","award":["19\/FFP\/6666"],"award-info":[{"award-number":["19\/FFP\/6666"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.neuropharm.2025.110319","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T11:57:15Z","timestamp":1737374235000},"page":"110319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The class-IIa HDAC inhibitor TMP269 promotes BMP-Smad signalling and is neuroprotective in in vitro and in vivo 6-hydroxydopamine models of Parkinson's disease"],"prefix":"10.1016","volume":"268","author":[{"given":"Adam G.","family":"O'Mahony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4055-2905","authenticated-orcid":false,"given":"Martina","family":"Mazzocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7229-7136","authenticated-orcid":false,"given":"Alex","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0123-2773","authenticated-orcid":false,"given":"Noelia","family":"Morales-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona","family":"Guinane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean L.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aideen M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard W.","family":"O'Keeffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110319_bib1","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1038\/s41598-017-06243-7","article-title":"Nucleocytoplasmic shuttling of histone deacetylase 9 controls activity-dependent thalamocortical axon branching","volume":"7","author":"Alchini","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110319_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12035-021-02569-6","article-title":"NME1 protects against neurotoxin-, alpha-synuclein- and LRRK2-induced neurite degeneration in cell models of Parkinson's disease","volume":"59","author":"Anantha","year":"2022","journal-title":"Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110319_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284480","article-title":"A comparison of machine learning approaches for the quantification of microglial cells in the brain of mice, rats and non-human primates","volume":"18","author":"Anwer","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110319_bib4","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2025.110319_bib5","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1038\/emboj.2012.160","article-title":"HDAC5 is a novel injury-regulated tubulin deacetylase controlling axon regeneration","volume":"31","author":"Cho","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.neuropharm.2025.110319_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neurobiolaging.2015.10.001","article-title":"A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson's disease","volume":"37","author":"Choong","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2025.110319_bib7","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s12035-014-8820-8","article-title":"Class-IIa histone deacetylase inhibition promotes the growth of neural processes and protects them against neurotoxic insult","volume":"51","author":"Collins","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110319_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/srep46464","article-title":"The BMP2 nuclear variant, nBMP2, is expressed in mouse hippocampus and impacts memory","volume":"7","author":"Cordner","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110319_bib9","doi-asserted-by":"crossref","unstructured":"Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S, Li T, Jiang Y, Wei S, Na Z, Xiao X, Li D. Signal Epigenetics-targeted drugs: current paradigms and future challenges. Transduct Target Ther. 9(1), 332. doi: 10.1038\/s41392-024-02039-0.","DOI":"10.1038\/s41392-024-02039-0"},{"key":"10.1016\/j.neuropharm.2025.110319_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0304-3940(99)00708-9","article-title":"Exposure of foetal mesencephalic cells to bone morphogenetic protein-2 enhances the survival of dopaminergic neurones in rat striatal grafts","volume":"275","author":"Espejo","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110319_bib11","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2025.110319_bib12","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1038\/s41598-020-62678-5","article-title":"Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity","volume":"10","author":"Francelle","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110319_bib13","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1093\/brain\/awaa367","article-title":"Growth differentiation factor 5 exerts neuroprotection in an alpha-synuclein rat model of Parkinson's disease","volume":"144","author":"Goulding","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2025.110319_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.parkreldis.2019.04.008","article-title":"Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or A53T \u03b1-synuclein","volume":"64","author":"Goulding","year":"2019","journal-title":"Parkinsonism Relat. Disorders"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110319_bib16","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1073\/pnas.96.9.4868","article-title":"Three proteins define a class of human histone deacetylases related to yeast Hda1p","volume":"96","author":"Grozinger","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110319_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/toxsci\/kfw157","article-title":"MC1568 inhibits thimerosal-induced apoptotic cell death by preventing HDAC4 up-regulation in neuronal cells and in rat prefrontal cortex","volume":"154","author":"Guida","year":"2016","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110319_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117278","article-title":"Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders","volume":"243","author":"Gupta","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110319_bib19","doi-asserted-by":"crossref","first-page":"14590","DOI":"10.1074\/jbc.M800264200","article-title":"Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis","volume":"283","author":"Ha","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110319_bib20","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1111\/bph.13208","article-title":"Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up\u2010regulation of neurotrophic factors","volume":"172","author":"Harrison","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110319_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jnc.14599","article-title":"The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease","volume":"148","author":"Harrison","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110319_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12017-014-8299-5","article-title":"Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons","volume":"16","author":"Hegarty","year":"2014","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.neuropharm.2025.110319_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.mcn.2013.06.006","article-title":"BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons","volume":"56","author":"Hegarty","year":"2013","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110319_bib25","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.14440\/jbm.2016.124","article-title":"Protocol for evaluation of neurotrophic strategies in Parkinson's disease-related dopaminergic and sympathetic neurons in vitro","volume":"3","author":"Hegarty","year":"2016","journal-title":"J. Biol. Methods"},{"key":"10.1016\/j.neuropharm.2025.110319_bib26","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1038\/s41598-017-08900-3","article-title":"Zeb2 is a negative regulator of midbrain dopaminergic axon growth and target innervation","volume":"7","author":"Hegarty","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110319_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2021.111376","article-title":"Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease","volume":"150","author":"Hou","year":"2021","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.neuropharm.2025.110319_bib28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neulet.2017.08.029","article-title":"Inhibition of HDAC6 increases acetylation of peroxiredoxin1\/2 and ameliorates 6-OHDA induced dopaminergic injury","volume":"658","author":"Jian","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110319_bib29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.parkreldis.2012.07.001","article-title":"RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study","volume":"19","author":"Johnston","year":"2013","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.neuropharm.2025.110319_bib30","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/mds.26354","article-title":"Disease-modifying strategies for Parkinson's disease","volume":"30","author":"Kalia","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110319_bib68","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/exnr.1998.6848","article-title":"Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat","volume":"152","author":"Kirik","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110319_bib31","article-title":"Acetylation of NDUFV1 induced by a newly synthesized HDAC6 inhibitor HGC rescues dopaminergic neuron loss in Parkinson models","volume":"24","author":"Li","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.neuropharm.2025.110319_bib32","article-title":"Class IIa histone deacetylase inhibition ameliorates acute kidney injury by suppressing renal tubular cell apoptosis and enhancing autophagy and proliferation","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110319_bib33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jns.2017.08.3235","article-title":"Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1","volume":"381","author":"Liu","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110319_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nchembio.1223","article-title":"Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group","volume":"9","author":"Lobera","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2025.110319_bib36","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1021\/jm049002a","article-title":"Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides","volume":"48","author":"Mai","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110319_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41577-024-01014-8","article-title":"Short-chain fatty acids: linking diet, the microbiome and immunity","volume":"24","author":"Mann","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2025.110319_bib38","doi-asserted-by":"crossref","DOI":"10.1042\/NS20200001","article-title":"The class II histone deacetylases as therapeutic targets for Parkinson's disease","volume":"4","author":"Mazzocchi","year":"2020","journal-title":"Neuronal Signal."},{"key":"10.1016\/j.neuropharm.2025.110319_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbi.2022.02.025","article-title":"Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease","volume":"102","author":"Mazzocchi","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2025.110319_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2021.103642","article-title":"LMK235, a small molecule inhibitor of HDAC4\/5, protects dopaminergic neurons against neurotoxin- and \u03b1-synuclein-induced degeneration in cellular models of Parkinson's disease","volume":"115","author":"Mazzocchi","year":"2021","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110319_bib43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fcell.2019.00191","article-title":"Gene Co-expression analysis identifies histone deacetylase 5 and 9 expression in midbrain dopamine neurons and as regulators of neurite growth via bone morphogenetic protein signaling","volume":"7","author":"Mazzocchi","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2025.110319_bib44","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.4103\/1673-5374.308089","article-title":"Short-chain fatty acids in the context of Parkinson's disease","volume":"16","author":"Metzdorf","year":"2021","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuropharm.2025.110319_bib45","first-page":"11","article-title":"Pathways for small molecule delivery to the central nervous system across the blood-brain barrier","volume":"6","author":"Mikitsh","year":"2014","journal-title":"Perspect. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110319_bib46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jnr.22547","article-title":"Small-molecule inhibitors of bone morphogenic protein and activin\/nodal signals promote highly efficient neural induction from human pluripotent stem cells","volume":"89","author":"Morizane","year":"2011","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2025.110319_bib47","doi-asserted-by":"crossref","first-page":"NS20170027","DOI":"10.1042\/NS20170027","article-title":"Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease","volume":"1","author":"O'Keeffe","year":"2017","journal-title":"Neuronal Signal."},{"key":"10.1016\/j.neuropharm.2025.110319_bib48","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","article-title":"Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test","volume":"15","author":"Olsson","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110319_bib49","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1242\/dev.101378","article-title":"Growth differentiation factor 5 is a key physiological regulator of dendrite growth during development","volume":"140","author":"Osorio","year":"2013","journal-title":"Development"},{"key":"10.1016\/j.neuropharm.2025.110319_bib50","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1074\/jbc.M115.675488","article-title":"Regulation of histone acetylation by autophagy in Parkinson disease","volume":"291","author":"Park","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110319_bib51","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.phrs.2015.11.024","article-title":"Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: therapeutic implications for Parkinson's disease","volume":"103","author":"Pinho","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2025.110319_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.expneurol.2019.03.011","article-title":"HDAC5 promotes optic nerve regeneration by activating the mTOR pathway","volume":"317","author":"Pita-Thomas","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110319_bib53","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.neuropharm.2012.01.026","article-title":"The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD","volume":"62","author":"Rane","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110319_bib55","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110319_bib56","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2164-13-298","article-title":"Distinct and overlapping gene regulatory networks in BMP- and HDAC-controlled cell fate determination in the embryonic forebrain","volume":"13","author":"Scholl","year":"2012","journal-title":"BMC Genom."},{"key":"10.1016\/j.neuropharm.2025.110319_bib57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1871527317666181004155136","article-title":"Epigenetics in neurodegenerative diseases: the role of histone deacetylases","volume":"18","author":"Sharma","year":"2019","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"key":"10.1016\/j.neuropharm.2025.110319_bib58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4103\/1673-5374.265562","article-title":"Neuroprotective mechanism of TMP269, a selective class IIA histone deacetylase inhibitor, after cerebral ischemia\/reperfusion injury","volume":"15","author":"Su","year":"2020","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuropharm.2025.110319_bib59","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neuron.2017.09.015","article-title":"HDAC5 and its target gene, Npas4, function in the nucleus accumbens to regulate cocaine-conditioned behaviors","volume":"96","author":"Taniguchi","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2025.110319_bib60","article-title":"Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model","volume":"12","author":"Taylor-Whiteley","year":"2019","journal-title":"Dis. Models Mechan."},{"key":"10.1016\/j.neuropharm.2025.110319_bib61","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1016\/j.cell.2023.07.023","article-title":"The projection-specific signals that establish functionally segregated dopaminergic synapses","volume":"186","author":"Terauchi","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2025.110319_bib62","doi-asserted-by":"crossref","first-page":"E8284","DOI":"10.1073\/pnas.1710442114","article-title":"Modelling Parkinson's disease pathology by combination of fibril seeds and alpha-synuclein overexpression in the rat brain","volume":"114","author":"Thakur","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110319_bib63","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1093\/brain\/awaa368","article-title":"BMP5\/7 protect dopaminergic neurons in an \u03b1-synuclein mouse model of Parkinson's disease","volume":"144","author":"Vitic","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2025.110319_bib64","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1007\/s12035-016-0199-2","article-title":"Nuclear accumulation of histone deacetylase 4 (HDAC4) exerts neurotoxicity in models of Parkinson's disease","volume":"54","author":"Wu","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110319_bib65","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-017-0149-0","article-title":"The SH-SY5Y cell line in Parkinson's disease research: a systematic review","volume":"12","author":"Xicoy","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2025.110319_bib66","article-title":"Valproic acid neuroprotection in the 6-OHDA model of Parkinson's disease is possibly related to its anti-inflammatory and HDAC inhibitory properties","volume":"2015","author":"Ximenes","year":"2015","journal-title":"J. Neurodegener Dis."},{"key":"10.1016\/j.neuropharm.2025.110319_bib67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nchembio.2007.54","article-title":"Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism","volume":"4","author":"Yu","year":"2008","journal-title":"Nat. Chem. Biol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:59:40Z","timestamp":1762214380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":62,"alternative-id":["S0028390825000255"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110319","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The class-IIa HDAC inhibitor TMP269 promotes BMP-Smad signalling and is neuroprotective in in vitro and in vivo 6-hydroxydopamine models of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110319"}}